ASCO 2026 | 177Lu-rosopatamab: an antibody-based PSMA radioligand in prostate cancer

So we presented basically part one of the phase three trial ProstACT, which is a global study. And that study is investigating the role of these TELX-591. You know, TLX591, also known as lutetium-177, rosopatamab tetraxetan. So it’s not a radioligand therapy. It’s a radioantibody therapeutic platform. So it basically finds PSMA. It has lutetium as a payload. So it’s a radiolabeled antibody drug conjugate, right? It was designed with a couple of concepts that we think might make it competitive in the prostate cancer landscape. You know, it has different characteristics. So it’s an antibody-based construct. So it’s a large molecule. It has a half-life in preclinical models, you know, over five days. It has low radiation delivered to salivary glands, low radiation delivered to the kidneys. And, you know, it has liver uptake and fecal excretion as well. So the recommended dose for TLX591 is actually a fixed dose of 76 millicuries, two times, 14 days apart. So basically, these pharmacokinetics and biodistribution features make a unique compound, certainly in the prostate cancer arena. And the goal of the trial was to, number one, prove safety and dosimetry features for TLX591. And then part two is to investigate whether or not the addition of TLX591 provides additional value to the standard of care for patients who progressed on prior ARPI in the context of metastatic castration-resistant disease, or APMR, which means androgen pathway modulation-resistant disease.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.